EMEA-001435-PIP02-16
Key facts
Invented name |
Vandaag
|
Active substance |
Anifrolumab
|
Therapeutic area |
Immunology-Rheumatology-Transplantation
|
Decision number |
P/0075/2018
|
PIP number |
EMEA-001435-PIP02-16
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
Treatment of Systemic Lupus Erythematosus (SLE)
|
Route(s) of administration |
|
Contact for public enquiries |
AstraZeneca AB (Sweden)
Tel. +46 8 55327591 |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|